# To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

> **NCT05223686** · PHASE1 · UNKNOWN · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Human CD19-CD22 Targeted T Cells Injection

## Key facts

- **NCT ID:** NCT05223686
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2023-06-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223686, "To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05223686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*